Treatment for Histamine Intolerance

Pharmacological Management

• The American Academy of Allergy, Asthma, and Immunology recommends a combination of H1 and H2 antihistamines, along with a low-histamine diet to reduce symptoms and improve quality of life in patients with histamine intolerance 1, 2
• Nonsedating H1 antihistamines (such as fexofenadine and cetirizine) are generally preferred and can be increased to 2-4 times the standard dose for better symptom control, reducing dermatologic manifestations like flushing and pruritus, as well as tachycardia and abdominal discomfort 1, 3
• H2 blockers (ranitidine, famotidine, cimetidine) can be used as first-line therapy for gastrointestinal symptoms and help H1 antihistamines attenuate cardiovascular symptoms when used in combination 3, 4
• Cromolyn sodium (oral formulation) reduces abdominal bloating, diarrhea, and cramps, and benefits may extend to neuropsychiatric manifestations, with a recommended dose of 200 mg 4 times daily (before meals and at bedtime) 1, 3, 4
• Doxepin, a potent H1 and H2 antihistamine with tricyclic antidepressant activity, may reduce central nervous system manifestations, but use with caution due to potential sedation and cognitive effects, especially in elderly patients 1, 4
• Leukotriene inhibitors (montelukast or zileuton) may reduce bronchospasm or gastrointestinal symptoms, particularly if urinary LTE4 levels are increased, and are most efficacious for dermatologic symptoms when used in conjunction with H1 antihistamines 1, 3
• Cyproheptadine, a sedating H1 antihistamine with extended anticholinergic and antiserotonergic activities, is particularly helpful for gastrointestinal symptoms 1, 3
• Corticosteroids may be useful for refractory symptoms at an initial oral dosage of 0.5 mg/kg/day, followed by a slow taper over 1-3 months, but are not recommended for long-term use due to side effects 1, 3
• Omalizumab may prevent anaphylactic episodes in some patients with mast cell activation syndrome, with a mechanism of action involving binding free IgE, preventing its binding to FcεRI 1, 2, 3

Acute Management of Severe Reactions

• For patients with a history of systemic anaphylaxis or airway angioedema, an epinephrine autoinjector is recommended, along with a bronchodilator (albuterol) for symptoms of bronchospasm, and supine positioning for those with recurrent hypotensive episodes 1, 2

Treatment for Histamine Intolerance

Pharmacological Management

• Antihistamines should never be used as monotherapy for severe reactions with cardiovascular or respiratory symptoms, as they have a slower onset of action compared to epinephrine, according to the American Academy of Allergy, Asthma, and Immunology 5
• For patients with a history of systemic anaphylaxis or airway angioedema, an epinephrine autoinjector is essential, as epinephrine is the cornerstone of management for severe reactions, based on guidelines from the American Academy of Allergy, Asthma, and Immunology 5

Special Considerations

• The histamine-1 receptor antagonist ebastine has shown promise in clinical trials for visceral hypersensitivity and may be beneficial for abdominal pain in histamine intolerance, as reported by the European Society of Gastrointestinal Motility 6
• For patients with overlapping irritable bowel syndrome symptoms, an integrated approach addressing both conditions may be necessary, according to the European Society of Gastrointestinal Motility 6